Michael Kreuter - Concepedia

Author

Michael Kreuter

Also Known As

Dirk Koschel, Felix Herth, I Kötter, Kreuter, M, Kreuter, M., Kreuter, Matthew W., Kreuter, Michael, M Kreuter, M, Kreuter, M. Kreuter

757

Publications

17.6K

Citations

H-Index

104

Concepts

All Affiliations

Heidelberg University German Center for Lung Research University Hospital Heidelberg Imperial College London Ruhrlandklinik

About

Michael Kreuter is an author at Heidelberg University specializing in medicine, pulmonary fibrosis, and pulmonary disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	41	5.2K
2	Health Sciences	7	7	251
3	Public Health	2	2	58
4	Nursing	1	1	37
5	Allergy	1	1	22

Michael Kreuter

155

Publications

12.6K

Citations

H-Index

Page 1

	Year	Citations
<scp>SARS</scp> ‐CoV‐2 receptor <scp>ACE</scp> 2 and <scp>TMPRSS</scp> 2 are primarily expressed in bronchial transient secretory cells Soeren Lukassen, Robert Lorenz Chua, Timo B. Trefzer, The EMBO Journal	2020	1K
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial Toby M. Maher, Tamera J. Corte, Aryeh Fischer, The Lancet Respiratory Medicine Antifibrotic TherapyAdvanced Lung DiseasePulmonary FibrosisPulmonary MedicineMedicine	2019	606
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown, The Lancet Respiratory Medicine Inbuild TrialParallel-group TrialAdvanced Lung DiseasePulmonary FibrosisPulmonary Medicine	2020	522
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial Jürgen Behr, Antje Prasse, Michael Kreuter, The Lancet Respiratory Medicine Antifibrotic TherapyAdvanced Lung DiseaseIdiopathic Pulmonary FibrosisPulmonary PharmacologyPulmonary Fibrosis	2021	490
SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells Soeren Lukassen, Robert Lorenz Chua, Timo B. Trefzer, The EMBO Journal Viral PathogenesisImmunologyInfectious Respiratory DiseaseSars-cov-2 Receptor Ace2Viral Structural Protein	2020	408
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities Peter M. George, Paolo Spagnolo, Michael Kreuter, The Lancet Respiratory Medicine Research PrioritiesAntifibrotic TherapyFibrosisPulmonary PathologyAdvanced Lung Disease	2020	332
Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis Michael Kreuter, Svenja Ehlers-Tenenbaum, Karin Palmowski, PLoS ONE	2016	309
Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype Diane R. Bielenberg, Yasuhiro Hida, Akio Shimizu, Journal of Clinical Investigation Endothelial CellsDermatologyCancer BiologyTumor BiologyMelanoma Result	2004	286
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial Carlo Vancheri, Michael Kreuter, Luca Richeldi, American Journal of Respiratory and Critical Care Medicine	2017	286
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements Anna‐Maria Hoffmann‐Vold, Toby M. Maher, E. Philpot, The Lancet Rheumatology Advanced Lung DiseaseSystemic SclerosisPulmonary FibrosisSclerodermaMedicine	2020	286

Page 1